NCT07198802Not yet recruiting
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 17 Jul 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Childhood cancers
- NCT number
- NCT07198802
What you commit to
- Study type: Observational
- Planned participants: 600
- From 1 Oct 2025 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
- Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.
Other
- The participants failed to obtain pathological and imaging data for various reasons;
Who the study is looking for
- Clearly diagnosed with nasopharyngeal carcinoma by pathology;
- Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
- Patients diagnosed in our hospital from January 2025 to December 2028;
- Have relatively complete clinical data;
- Age between 15 and 75 years old;
Age in the registry: 15 years to 75 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.